Ro's Shift to Care Platform
Ro
Once branded Wegovy supply was put on the same rails for the biggest telehealth players, the real moat moved from finding inventory to running a better obesity care machine. Ro could no longer win just by having access to authentic drug supply. It had to win on the parts patients actually feel over months, getting approved, getting labs done, adjusting dose, managing side effects, receiving medication on time, and staying engaged long enough to remain on treatment.
-
Novo Nordisk launched NovoCare Pharmacy in March 2025 with Wegovy at $499 per month for cash paying patients, then added direct access for Ro, Hims & Hers, and LifeMD in April 2025. That made manufacturer sourced branded supply far less unique across the top D2C platforms.
-
Ro’s answer is workflow depth. Ro Body charges a monthly care fee on top of medication and uses owned pharmacies, lab capabilities, home testing, and clinician follow up to manage dose titration and monitoring. That matters because GLP-1 treatment is an ongoing care loop, not a one time prescription.
-
This changes the comparison set. Ro starts to look less like a simple online pharmacy and more like programs such as Noom and Virta, where retention comes from coaching, care plans, and measurable follow through. In employer channels especially, buyers increasingly want managed programs, not just cheaper prescriptions.
The next phase favors platforms that can turn cheap drug access into durable longitudinal care. As branded supply and pricing standardize, growth shifts toward whoever keeps patients adherent longest, handles insurance and refill friction best, and can sell that operating system to employers, payers, and drug makers launching the next wave of obesity treatments.